Diabetes downregulates the antimicrobial peptide psoriasin and increases E. coli burden in the urinary bladder.
Soumitra MohantyWitchuda KamolvitAndrea ScheffschickAnneli BjörklundJonas ToviAlexander EspinosaKerstin BrismarThomas NyströmJens-Michael SchröderClaes-Goran OstensonPontus AspenströmHanna BraunerAnnelie BraunerPublished in: Nature communications (2022)
Diabetes is known to increase susceptibility to infections, partly due to impaired granulocyte function and changes in the innate immunity. Here, we investigate the effect of diabetes, and high glucose on the expression of the antimicrobial peptide, psoriasin and the putative consequences for E. coli urinary tract infection. Blood, urine, and urine exfoliated cells from patients are studied. The influence of glucose and insulin is examined during hyperglycemic clamps in individuals with prediabetes and in euglycemic hyperinsulinemic clamped patients with type 1 diabetes. Important findings are confirmed in vivo in type 2 diabetic mice and verified in human uroepithelial cell lines. High glucose concentrations induce lower psoriasin levels and impair epithelial barrier function together with altering cell membrane proteins and cytoskeletal elements, resulting in increasing bacterial burden. Estradiol treatment restores the cellular function with increasing psoriasin and bacterial killing in uroepithelial cells, confirming its importance during urinary tract infection in hyperglycemia. In conclusion, our findings present the effects and underlying mechanisms of high glucose compromising innate immunity.
Keyphrases
- high glucose
- urinary tract infection
- endothelial cells
- type diabetes
- glycemic control
- cardiovascular disease
- end stage renal disease
- escherichia coli
- induced apoptosis
- chronic kidney disease
- blood glucose
- ejection fraction
- newly diagnosed
- poor prognosis
- prognostic factors
- oxidative stress
- risk factors
- cell cycle arrest
- endoplasmic reticulum stress
- insulin resistance
- induced pluripotent stem cells
- signaling pathway
- recombinant human